NCT05222425View on ClinicalTrials.gov

Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3

PHASE3UnknownINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

October 15, 2022

Study Completion Date

December 7, 2022

Conditions
Sars-cov-2
Interventions
DRUG

Xagrotin

A herbal compound

DRUG

Green tea

Normal green tea

Trial Locations (1)

Unknown

Directorate of health of Sulaimani, Iraq -KRG, Sulaymaniyah

Sponsors

Lead Sponsor

Biomad AS
All Listed Sponsors
lead

Biomad AS

INDUSTRY

NCT05222425 - Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3 | Biotech Hunter | Biotech Hunter